Pfizer (PFE) Tops Q3 EPS by 44c, Beats on Revenue; Offers FY24 Guidance
Tweet
Share
E-mail
Get Alerts PFE Hot Sheet
Price: $25.21 -2.74%
Revenue Growth %: -1.8%
Financial Fact:
Net income attributable to Pfizer Inc.: 1.32B
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: -1.8%
Financial Fact:
Net income attributable to Pfizer Inc.: 1.32B
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Pfizer (NYSE: PFE) reported Q3 EPS of $1.06, $0.44 better than the analyst estimate of $0.62. Revenue for the quarter came in at $17.7 billion versus the consensus estimate of $14.92 billion.
GUIDANCE:
Pfizer sees FY2024 EPS of $2.75-$2.95, versus the consensus of $2.65. Pfizer sees FY2024 revenue of $61-64 billion, versus the consensus of $61.2 billion.
For earnings history and earnings-related data on Pfizer (PFE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pfizer reaffirms 2026 guidance after CFO transition news
- JPMorgan Upgrades YDUQS Participacoes SA (YDUQ3:BZ) to Overweight
- JPMorgan Downgrades Anima Holding SA (ANIM3:BZ) to Neutral
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
